nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Eyelid disorder—Rivastigmine—Alzheimer's disease	0.0475	0.0565	CcSEcCtD
Apraclonidine—Syncope vasovagal—Rivastigmine—Alzheimer's disease	0.0311	0.0369	CcSEcCtD
Apraclonidine—Blepharospasm—Rivastigmine—Alzheimer's disease	0.0253	0.0301	CcSEcCtD
Apraclonidine—Presyncope—Rivastigmine—Alzheimer's disease	0.0187	0.0223	CcSEcCtD
Apraclonidine—Upset stomach—Galantamine—Alzheimer's disease	0.0132	0.0157	CcSEcCtD
Apraclonidine—Blepharitis—Donepezil—Alzheimer's disease	0.0109	0.013	CcSEcCtD
Apraclonidine—Visual acuity reduced—Memantine—Alzheimer's disease	0.0102	0.0122	CcSEcCtD
Apraclonidine—Upset stomach—Donepezil—Alzheimer's disease	0.0102	0.0122	CcSEcCtD
Apraclonidine—Blepharitis—Memantine—Alzheimer's disease	0.0099	0.0118	CcSEcCtD
Apraclonidine—Blepharitis—Rivastigmine—Alzheimer's disease	0.00969	0.0115	CcSEcCtD
Apraclonidine—Eye irritation—Donepezil—Alzheimer's disease	0.00786	0.00934	CcSEcCtD
Apraclonidine—Vasodilation procedure—Donepezil—Alzheimer's disease	0.00763	0.00907	CcSEcCtD
Apraclonidine—Vasodilation—Donepezil—Alzheimer's disease	0.00763	0.00907	CcSEcCtD
Apraclonidine—Pallor—Memantine—Alzheimer's disease	0.00735	0.00873	CcSEcCtD
Apraclonidine—Pallor—Rivastigmine—Alzheimer's disease	0.00719	0.00854	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Galantamine—Alzheimer's disease	0.00623	0.00741	CcSEcCtD
Apraclonidine—Coordination abnormal—Memantine—Alzheimer's disease	0.0062	0.00737	CcSEcCtD
Apraclonidine—Dry eye—Donepezil—Alzheimer's disease	0.0062	0.00736	CcSEcCtD
Apraclonidine—Inflammation—Rivastigmine—Alzheimer's disease	0.00614	0.0073	CcSEcCtD
Apraclonidine—Coordination abnormal—Rivastigmine—Alzheimer's disease	0.00607	0.00721	CcSEcCtD
Apraclonidine—Dermatitis contact—Rivastigmine—Alzheimer's disease	0.00589	0.007	CcSEcCtD
Apraclonidine—Abnormal vision—Donepezil—Alzheimer's disease	0.00585	0.00695	CcSEcCtD
Apraclonidine—Abnormal vision—Memantine—Alzheimer's disease	0.00531	0.00631	CcSEcCtD
Apraclonidine—Libido decreased—Donepezil—Alzheimer's disease	0.00525	0.00624	CcSEcCtD
Apraclonidine—Abdominal discomfort—Galantamine—Alzheimer's disease	0.00521	0.00619	CcSEcCtD
Apraclonidine—Abnormal vision—Rivastigmine—Alzheimer's disease	0.0052	0.00618	CcSEcCtD
Apraclonidine—Eye pain—Memantine—Alzheimer's disease	0.0049	0.00582	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Donepezil—Alzheimer's disease	0.00483	0.00574	CcSEcCtD
Apraclonidine—Eye pain—Rivastigmine—Alzheimer's disease	0.00479	0.00569	CcSEcCtD
Apraclonidine—Libido decreased—Memantine—Alzheimer's disease	0.00477	0.00567	CcSEcCtD
Apraclonidine—Face oedema—Donepezil—Alzheimer's disease	0.0047	0.00559	CcSEcCtD
Apraclonidine—Libido decreased—Rivastigmine—Alzheimer's disease	0.00466	0.00554	CcSEcCtD
Apraclonidine—Irritability—Donepezil—Alzheimer's disease	0.00465	0.00552	CcSEcCtD
Apraclonidine—Bradycardia—Galantamine—Alzheimer's disease	0.00443	0.00526	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Memantine—Alzheimer's disease	0.00439	0.00521	CcSEcCtD
Apraclonidine—Rhinitis—Galantamine—Alzheimer's disease	0.00436	0.00518	CcSEcCtD
Apraclonidine—Nasopharyngitis—Donepezil—Alzheimer's disease	0.00435	0.00518	CcSEcCtD
Apraclonidine—Haemorrhage—Galantamine—Alzheimer's disease	0.00435	0.00517	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Rivastigmine—Alzheimer's disease	0.00429	0.0051	CcSEcCtD
Apraclonidine—Oedema peripheral—Galantamine—Alzheimer's disease	0.00428	0.00509	CcSEcCtD
Apraclonidine—Irritability—Memantine—Alzheimer's disease	0.00422	0.00502	CcSEcCtD
Apraclonidine—Asthma—Donepezil—Alzheimer's disease	0.00421	0.005	CcSEcCtD
Apraclonidine—Visual impairment—Galantamine—Alzheimer's disease	0.00419	0.00498	CcSEcCtD
Apraclonidine—Face oedema—Rivastigmine—Alzheimer's disease	0.00418	0.00496	CcSEcCtD
Apraclonidine—Eye disorder—Galantamine—Alzheimer's disease	0.00406	0.00483	CcSEcCtD
Apraclonidine—Abdominal discomfort—Donepezil—Alzheimer's disease	0.00403	0.0048	CcSEcCtD
Apraclonidine—Nasopharyngitis—Memantine—Alzheimer's disease	0.00395	0.0047	CcSEcCtD
Apraclonidine—Angiopathy—Galantamine—Alzheimer's disease	0.00394	0.00469	CcSEcCtD
Apraclonidine—Arrhythmia—Galantamine—Alzheimer's disease	0.00388	0.00462	CcSEcCtD
Apraclonidine—Nasopharyngitis—Rivastigmine—Alzheimer's disease	0.00387	0.0046	CcSEcCtD
Apraclonidine—Asthma—Memantine—Alzheimer's disease	0.00382	0.00454	CcSEcCtD
Apraclonidine—Mental disorder—Galantamine—Alzheimer's disease	0.00381	0.00453	CcSEcCtD
Apraclonidine—Infestation NOS—Donepezil—Alzheimer's disease	0.00375	0.00446	CcSEcCtD
Apraclonidine—Infestation—Donepezil—Alzheimer's disease	0.00375	0.00446	CcSEcCtD
Apraclonidine—Tension—Galantamine—Alzheimer's disease	0.00371	0.00441	CcSEcCtD
Apraclonidine—Dysgeusia—Galantamine—Alzheimer's disease	0.00371	0.0044	CcSEcCtD
Apraclonidine—Nervousness—Galantamine—Alzheimer's disease	0.00368	0.00437	CcSEcCtD
Apraclonidine—Conjunctivitis—Donepezil—Alzheimer's disease	0.00365	0.00434	CcSEcCtD
Apraclonidine—Vision blurred—Galantamine—Alzheimer's disease	0.00357	0.00424	CcSEcCtD
Apraclonidine—Ill-defined disorder—Galantamine—Alzheimer's disease	0.00351	0.00417	CcSEcCtD
Apraclonidine—Bradycardia—Donepezil—Alzheimer's disease	0.00343	0.00408	CcSEcCtD
Apraclonidine—Malaise—Galantamine—Alzheimer's disease	0.00341	0.00406	CcSEcCtD
Apraclonidine—Infestation NOS—Memantine—Alzheimer's disease	0.00341	0.00405	CcSEcCtD
Apraclonidine—Infestation—Memantine—Alzheimer's disease	0.00341	0.00405	CcSEcCtD
Apraclonidine—Syncope—Galantamine—Alzheimer's disease	0.00339	0.00403	CcSEcCtD
Apraclonidine—Rhinitis—Donepezil—Alzheimer's disease	0.00338	0.00401	CcSEcCtD
Apraclonidine—Haemorrhage—Donepezil—Alzheimer's disease	0.00337	0.004	CcSEcCtD
Apraclonidine—Palpitations—Galantamine—Alzheimer's disease	0.00334	0.00397	CcSEcCtD
Apraclonidine—Pharyngitis—Donepezil—Alzheimer's disease	0.00334	0.00397	CcSEcCtD
Apraclonidine—Infestation NOS—Rivastigmine—Alzheimer's disease	0.00333	0.00396	CcSEcCtD
Apraclonidine—Infestation—Rivastigmine—Alzheimer's disease	0.00333	0.00396	CcSEcCtD
Apraclonidine—Oedema peripheral—Donepezil—Alzheimer's disease	0.00332	0.00394	CcSEcCtD
Apraclonidine—Conjunctivitis—Memantine—Alzheimer's disease	0.00331	0.00394	CcSEcCtD
Apraclonidine—Visual impairment—Donepezil—Alzheimer's disease	0.00325	0.00386	CcSEcCtD
Apraclonidine—Conjunctivitis—Rivastigmine—Alzheimer's disease	0.00324	0.00385	CcSEcCtD
Apraclonidine—Myalgia—Galantamine—Alzheimer's disease	0.00322	0.00383	CcSEcCtD
Apraclonidine—Chest pain—Galantamine—Alzheimer's disease	0.00322	0.00383	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.0032	0.0038	CcSEcCtD
Apraclonidine—Discomfort—Galantamine—Alzheimer's disease	0.00318	0.00378	CcSEcCtD
Apraclonidine—Dry mouth—Galantamine—Alzheimer's disease	0.00315	0.00374	CcSEcCtD
Apraclonidine—Bradycardia—Memantine—Alzheimer's disease	0.00311	0.0037	CcSEcCtD
Apraclonidine—Rhinitis—Memantine—Alzheimer's disease	0.00307	0.00364	CcSEcCtD
Apraclonidine—Haemorrhage—Memantine—Alzheimer's disease	0.00306	0.00364	CcSEcCtD
Apraclonidine—Bradycardia—Rivastigmine—Alzheimer's disease	0.00305	0.00362	CcSEcCtD
Apraclonidine—Pharyngitis—Memantine—Alzheimer's disease	0.00304	0.00361	CcSEcCtD
Apraclonidine—Nervous system disorder—Galantamine—Alzheimer's disease	0.00303	0.0036	CcSEcCtD
Apraclonidine—Oedema peripheral—Memantine—Alzheimer's disease	0.00301	0.00358	CcSEcCtD
Apraclonidine—Arrhythmia—Donepezil—Alzheimer's disease	0.00301	0.00358	CcSEcCtD
Apraclonidine—Rhinitis—Rivastigmine—Alzheimer's disease	0.003	0.00357	CcSEcCtD
Apraclonidine—Skin disorder—Galantamine—Alzheimer's disease	0.003	0.00357	CcSEcCtD
Apraclonidine—Haemorrhage—Rivastigmine—Alzheimer's disease	0.00299	0.00356	CcSEcCtD
Apraclonidine—Pharyngitis—Rivastigmine—Alzheimer's disease	0.00297	0.00353	CcSEcCtD
Apraclonidine—Mental disorder—Donepezil—Alzheimer's disease	0.00295	0.00351	CcSEcCtD
Apraclonidine—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.00295	0.0035	CcSEcCtD
Apraclonidine—Visual impairment—Memantine—Alzheimer's disease	0.00295	0.0035	CcSEcCtD
Apraclonidine—Erythema—Donepezil—Alzheimer's disease	0.00293	0.00349	CcSEcCtD
Apraclonidine—Visual impairment—Rivastigmine—Alzheimer's disease	0.00288	0.00343	CcSEcCtD
Apraclonidine—Tension—Donepezil—Alzheimer's disease	0.00288	0.00342	CcSEcCtD
Apraclonidine—Dysgeusia—Donepezil—Alzheimer's disease	0.00287	0.00341	CcSEcCtD
Apraclonidine—Eye disorder—Memantine—Alzheimer's disease	0.00286	0.0034	CcSEcCtD
Apraclonidine—Nervousness—Donepezil—Alzheimer's disease	0.00285	0.00339	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.00281	0.00334	CcSEcCtD
Apraclonidine—Eye disorder—Rivastigmine—Alzheimer's disease	0.0028	0.00332	CcSEcCtD
Apraclonidine—Insomnia—Galantamine—Alzheimer's disease	0.00279	0.00332	CcSEcCtD
Apraclonidine—Angiopathy—Memantine—Alzheimer's disease	0.00278	0.0033	CcSEcCtD
Apraclonidine—Paraesthesia—Galantamine—Alzheimer's disease	0.00277	0.0033	CcSEcCtD
Apraclonidine—Vision blurred—Donepezil—Alzheimer's disease	0.00276	0.00328	CcSEcCtD
Apraclonidine—Mediastinal disorder—Memantine—Alzheimer's disease	0.00276	0.00328	CcSEcCtD
Apraclonidine—Somnolence—Galantamine—Alzheimer's disease	0.00275	0.00326	CcSEcCtD
Apraclonidine—Arrhythmia—Memantine—Alzheimer's disease	0.00273	0.00325	CcSEcCtD
Apraclonidine—Ill-defined disorder—Donepezil—Alzheimer's disease	0.00272	0.00323	CcSEcCtD
Apraclonidine—Angiopathy—Rivastigmine—Alzheimer's disease	0.00271	0.00323	CcSEcCtD
Apraclonidine—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.0027	0.00321	CcSEcCtD
Apraclonidine—Mental disorder—Memantine—Alzheimer's disease	0.00268	0.00318	CcSEcCtD
Apraclonidine—Arrhythmia—Rivastigmine—Alzheimer's disease	0.00267	0.00318	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.00267	0.00317	CcSEcCtD
Apraclonidine—Fatigue—Galantamine—Alzheimer's disease	0.00266	0.00316	CcSEcCtD
Apraclonidine—Malaise—Donepezil—Alzheimer's disease	0.00264	0.00314	CcSEcCtD
Apraclonidine—Constipation—Galantamine—Alzheimer's disease	0.00264	0.00314	CcSEcCtD
Apraclonidine—Syncope—Donepezil—Alzheimer's disease	0.00263	0.00313	CcSEcCtD
Apraclonidine—Mental disorder—Rivastigmine—Alzheimer's disease	0.00262	0.00312	CcSEcCtD
Apraclonidine—Tension—Memantine—Alzheimer's disease	0.00261	0.00311	CcSEcCtD
Apraclonidine—Dysgeusia—Memantine—Alzheimer's disease	0.00261	0.0031	CcSEcCtD
Apraclonidine—Erythema—Rivastigmine—Alzheimer's disease	0.0026	0.0031	CcSEcCtD
Apraclonidine—Nervousness—Memantine—Alzheimer's disease	0.00259	0.00307	CcSEcCtD
Apraclonidine—Tension—Rivastigmine—Alzheimer's disease	0.00256	0.00304	CcSEcCtD
Apraclonidine—Dysgeusia—Rivastigmine—Alzheimer's disease	0.00255	0.00303	CcSEcCtD
Apraclonidine—Feeling abnormal—Galantamine—Alzheimer's disease	0.00254	0.00302	CcSEcCtD
Apraclonidine—Nervousness—Rivastigmine—Alzheimer's disease	0.00253	0.00301	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.00253	0.003	CcSEcCtD
Apraclonidine—Vision blurred—Memantine—Alzheimer's disease	0.00251	0.00298	CcSEcCtD
Apraclonidine—Chest pain—Donepezil—Alzheimer's disease	0.0025	0.00297	CcSEcCtD
Apraclonidine—Myalgia—Donepezil—Alzheimer's disease	0.0025	0.00297	CcSEcCtD
Apraclonidine—Ill-defined disorder—Memantine—Alzheimer's disease	0.00247	0.00294	CcSEcCtD
Apraclonidine—Discomfort—Donepezil—Alzheimer's disease	0.00247	0.00293	CcSEcCtD
Apraclonidine—Vision blurred—Rivastigmine—Alzheimer's disease	0.00245	0.00292	CcSEcCtD
Apraclonidine—Dry mouth—Donepezil—Alzheimer's disease	0.00244	0.0029	CcSEcCtD
Apraclonidine—Abdominal pain—Galantamine—Alzheimer's disease	0.00244	0.0029	CcSEcCtD
Apraclonidine—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.00242	0.00287	CcSEcCtD
Apraclonidine—Malaise—Memantine—Alzheimer's disease	0.0024	0.00285	CcSEcCtD
Apraclonidine—Oedema—Donepezil—Alzheimer's disease	0.00239	0.00284	CcSEcCtD
Apraclonidine—Syncope—Memantine—Alzheimer's disease	0.00239	0.00284	CcSEcCtD
Apraclonidine—Infection—Donepezil—Alzheimer's disease	0.00238	0.00283	CcSEcCtD
Apraclonidine—Palpitations—Memantine—Alzheimer's disease	0.00235	0.0028	CcSEcCtD
Apraclonidine—Malaise—Rivastigmine—Alzheimer's disease	0.00235	0.00279	CcSEcCtD
Apraclonidine—Nervous system disorder—Donepezil—Alzheimer's disease	0.00235	0.00279	CcSEcCtD
Apraclonidine—Syncope—Rivastigmine—Alzheimer's disease	0.00234	0.00278	CcSEcCtD
Apraclonidine—Palpitations—Rivastigmine—Alzheimer's disease	0.0023	0.00274	CcSEcCtD
Apraclonidine—Hypersensitivity—Galantamine—Alzheimer's disease	0.00228	0.0027	CcSEcCtD
Apraclonidine—Myalgia—Memantine—Alzheimer's disease	0.00227	0.00269	CcSEcCtD
Apraclonidine—Chest pain—Memantine—Alzheimer's disease	0.00227	0.00269	CcSEcCtD
Apraclonidine—Discomfort—Memantine—Alzheimer's disease	0.00224	0.00266	CcSEcCtD
Apraclonidine—Myalgia—Rivastigmine—Alzheimer's disease	0.00222	0.00264	CcSEcCtD
Apraclonidine—Chest pain—Rivastigmine—Alzheimer's disease	0.00222	0.00264	CcSEcCtD
Apraclonidine—Dry mouth—Memantine—Alzheimer's disease	0.00222	0.00264	CcSEcCtD
Apraclonidine—Asthenia—Galantamine—Alzheimer's disease	0.00222	0.00263	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.0022	0.00262	CcSEcCtD
Apraclonidine—Discomfort—Rivastigmine—Alzheimer's disease	0.00219	0.0026	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.00218	0.00259	CcSEcCtD
Apraclonidine—Oedema—Memantine—Alzheimer's disease	0.00217	0.00258	CcSEcCtD
Apraclonidine—Dry mouth—Rivastigmine—Alzheimer's disease	0.00217	0.00258	CcSEcCtD
Apraclonidine—Insomnia—Donepezil—Alzheimer's disease	0.00216	0.00257	CcSEcCtD
Apraclonidine—Infection—Memantine—Alzheimer's disease	0.00216	0.00257	CcSEcCtD
Apraclonidine—Paraesthesia—Donepezil—Alzheimer's disease	0.00215	0.00255	CcSEcCtD
Apraclonidine—Dyspnoea—Donepezil—Alzheimer's disease	0.00213	0.00254	CcSEcCtD
Apraclonidine—Nervous system disorder—Memantine—Alzheimer's disease	0.00213	0.00253	CcSEcCtD
Apraclonidine—Somnolence—Donepezil—Alzheimer's disease	0.00213	0.00253	CcSEcCtD
Apraclonidine—Oedema—Rivastigmine—Alzheimer's disease	0.00213	0.00253	CcSEcCtD
Apraclonidine—Diarrhoea—Galantamine—Alzheimer's disease	0.00211	0.00251	CcSEcCtD
Apraclonidine—Infection—Rivastigmine—Alzheimer's disease	0.00211	0.00251	CcSEcCtD
Apraclonidine—Skin disorder—Memantine—Alzheimer's disease	0.00211	0.00251	CcSEcCtD
Apraclonidine—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.00208	0.00248	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.00207	0.00246	CcSEcCtD
Apraclonidine—Skin disorder—Rivastigmine—Alzheimer's disease	0.00206	0.00245	CcSEcCtD
Apraclonidine—Fatigue—Donepezil—Alzheimer's disease	0.00206	0.00245	CcSEcCtD
Apraclonidine—Pain—Donepezil—Alzheimer's disease	0.00205	0.00243	CcSEcCtD
Apraclonidine—Constipation—Donepezil—Alzheimer's disease	0.00205	0.00243	CcSEcCtD
Apraclonidine—Dizziness—Galantamine—Alzheimer's disease	0.00204	0.00243	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.00198	0.00235	CcSEcCtD
Apraclonidine—Feeling abnormal—Donepezil—Alzheimer's disease	0.00197	0.00234	CcSEcCtD
Apraclonidine—Insomnia—Memantine—Alzheimer's disease	0.00197	0.00234	CcSEcCtD
Apraclonidine—Vomiting—Galantamine—Alzheimer's disease	0.00196	0.00233	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.00196	0.00233	CcSEcCtD
Apraclonidine—Paraesthesia—Memantine—Alzheimer's disease	0.00195	0.00232	CcSEcCtD
Apraclonidine—Dermatitis—Galantamine—Alzheimer's disease	0.00195	0.00231	CcSEcCtD
Apraclonidine—Dyspnoea—Memantine—Alzheimer's disease	0.00194	0.0023	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.00194	0.0023	CcSEcCtD
Apraclonidine—Headache—Galantamine—Alzheimer's disease	0.00193	0.0023	CcSEcCtD
Apraclonidine—Somnolence—Memantine—Alzheimer's disease	0.00193	0.0023	CcSEcCtD
Apraclonidine—Insomnia—Rivastigmine—Alzheimer's disease	0.00192	0.00229	CcSEcCtD
Apraclonidine—Paraesthesia—Rivastigmine—Alzheimer's disease	0.00191	0.00227	CcSEcCtD
Apraclonidine—Dyspnoea—Rivastigmine—Alzheimer's disease	0.0019	0.00225	CcSEcCtD
Apraclonidine—Abdominal pain—Donepezil—Alzheimer's disease	0.00189	0.00225	CcSEcCtD
Apraclonidine—Somnolence—Rivastigmine—Alzheimer's disease	0.00189	0.00225	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.00188	0.00223	CcSEcCtD
Apraclonidine—Fatigue—Memantine—Alzheimer's disease	0.00187	0.00223	CcSEcCtD
Apraclonidine—Pain—Memantine—Alzheimer's disease	0.00186	0.00221	CcSEcCtD
Apraclonidine—Constipation—Memantine—Alzheimer's disease	0.00186	0.00221	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.00184	0.00218	CcSEcCtD
Apraclonidine—Nausea—Galantamine—Alzheimer's disease	0.00183	0.00218	CcSEcCtD
Apraclonidine—Fatigue—Rivastigmine—Alzheimer's disease	0.00183	0.00218	CcSEcCtD
Apraclonidine—Pain—Rivastigmine—Alzheimer's disease	0.00182	0.00216	CcSEcCtD
Apraclonidine—Constipation—Rivastigmine—Alzheimer's disease	0.00182	0.00216	CcSEcCtD
Apraclonidine—Feeling abnormal—Memantine—Alzheimer's disease	0.00179	0.00213	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Memantine—Alzheimer's disease	0.00178	0.00211	CcSEcCtD
Apraclonidine—Hypersensitivity—Donepezil—Alzheimer's disease	0.00176	0.0021	CcSEcCtD
Apraclonidine—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.00175	0.00208	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.00174	0.00207	CcSEcCtD
Apraclonidine—Abdominal pain—Memantine—Alzheimer's disease	0.00172	0.00204	CcSEcCtD
Apraclonidine—Asthenia—Donepezil—Alzheimer's disease	0.00172	0.00204	CcSEcCtD
Apraclonidine—Pruritus—Donepezil—Alzheimer's disease	0.00169	0.00201	CcSEcCtD
Apraclonidine—Abdominal pain—Rivastigmine—Alzheimer's disease	0.00168	0.002	CcSEcCtD
Apraclonidine—Diarrhoea—Donepezil—Alzheimer's disease	0.00164	0.00195	CcSEcCtD
Apraclonidine—Hypersensitivity—Memantine—Alzheimer's disease	0.0016	0.0019	CcSEcCtD
Apraclonidine—Dizziness—Donepezil—Alzheimer's disease	0.00158	0.00188	CcSEcCtD
Apraclonidine—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.00157	0.00186	CcSEcCtD
Apraclonidine—Asthenia—Memantine—Alzheimer's disease	0.00156	0.00185	CcSEcCtD
Apraclonidine—Pruritus—Memantine—Alzheimer's disease	0.00154	0.00183	CcSEcCtD
Apraclonidine—Asthenia—Rivastigmine—Alzheimer's disease	0.00153	0.00181	CcSEcCtD
Apraclonidine—Vomiting—Donepezil—Alzheimer's disease	0.00152	0.00181	CcSEcCtD
Apraclonidine—Dermatitis—Donepezil—Alzheimer's disease	0.00151	0.00179	CcSEcCtD
Apraclonidine—Pruritus—Rivastigmine—Alzheimer's disease	0.0015	0.00179	CcSEcCtD
Apraclonidine—Headache—Donepezil—Alzheimer's disease	0.0015	0.00178	CcSEcCtD
Apraclonidine—Diarrhoea—Memantine—Alzheimer's disease	0.00149	0.00177	CcSEcCtD
Apraclonidine—Diarrhoea—Rivastigmine—Alzheimer's disease	0.00145	0.00173	CcSEcCtD
Apraclonidine—Dizziness—Memantine—Alzheimer's disease	0.00144	0.00171	CcSEcCtD
Apraclonidine—Nausea—Donepezil—Alzheimer's disease	0.00142	0.00169	CcSEcCtD
Apraclonidine—Dizziness—Rivastigmine—Alzheimer's disease	0.00141	0.00167	CcSEcCtD
Apraclonidine—Vomiting—Memantine—Alzheimer's disease	0.00138	0.00164	CcSEcCtD
Apraclonidine—Dermatitis—Memantine—Alzheimer's disease	0.00137	0.00163	CcSEcCtD
Apraclonidine—Headache—Memantine—Alzheimer's disease	0.00136	0.00162	CcSEcCtD
Apraclonidine—Vomiting—Rivastigmine—Alzheimer's disease	0.00135	0.00161	CcSEcCtD
Apraclonidine—Dermatitis—Rivastigmine—Alzheimer's disease	0.00134	0.00159	CcSEcCtD
Apraclonidine—Headache—Rivastigmine—Alzheimer's disease	0.00133	0.00158	CcSEcCtD
Apraclonidine—Nausea—Memantine—Alzheimer's disease	0.00129	0.00153	CcSEcCtD
Apraclonidine—Nausea—Rivastigmine—Alzheimer's disease	0.00126	0.0015	CcSEcCtD
Apraclonidine—ADRA2C—Signaling by GPCR—HTR2A—Alzheimer's disease	7.89e-05	0.000497	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CALM1—Alzheimer's disease	7.88e-05	0.000497	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ABCA1—Alzheimer's disease	7.88e-05	0.000497	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GSK3A—Alzheimer's disease	7.84e-05	0.000494	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—NOS3—Alzheimer's disease	7.78e-05	0.00049	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR5—Alzheimer's disease	7.76e-05	0.000489	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NPS—Alzheimer's disease	7.75e-05	0.000488	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—A2M—Alzheimer's disease	7.72e-05	0.000487	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APP—Alzheimer's disease	7.71e-05	0.000486	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PPP3CA—Alzheimer's disease	7.71e-05	0.000486	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—F2—Alzheimer's disease	7.62e-05	0.00048	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PRKCG—Alzheimer's disease	7.61e-05	0.00048	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTK2B—Alzheimer's disease	7.6e-05	0.000479	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—HTR2A—Alzheimer's disease	7.6e-05	0.000479	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ENO1—Alzheimer's disease	7.53e-05	0.000474	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS1—Alzheimer's disease	7.53e-05	0.000474	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PSEN2—Alzheimer's disease	7.48e-05	0.000471	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PRKCG—Alzheimer's disease	7.44e-05	0.000469	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—F2—Alzheimer's disease	7.41e-05	0.000467	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NPY—Alzheimer's disease	7.41e-05	0.000467	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GAB2—Alzheimer's disease	7.39e-05	0.000466	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SST—Alzheimer's disease	7.39e-05	0.000466	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NTRK2—Alzheimer's disease	7.39e-05	0.000466	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—VEGFA—Alzheimer's disease	7.39e-05	0.000466	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP2D6—Alzheimer's disease	7.38e-05	0.000465	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CALM1—Alzheimer's disease	7.36e-05	0.000464	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IAPP—Alzheimer's disease	7.36e-05	0.000464	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GSK3A—Alzheimer's disease	7.33e-05	0.000462	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PLCB1—Alzheimer's disease	7.28e-05	0.000459	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR5—Alzheimer's disease	7.21e-05	0.000455	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APP—Alzheimer's disease	7.2e-05	0.000454	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CRH—Alzheimer's disease	7.15e-05	0.00045	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HTR2A—Alzheimer's disease	7.06e-05	0.000445	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR5—Alzheimer's disease	7.05e-05	0.000444	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—BCHE—Alzheimer's disease	7e-05	0.000441	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—Alzheimer's disease	6.94e-05	0.000437	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—F2—Alzheimer's disease	6.92e-05	0.000436	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PRKCG—Alzheimer's disease	6.91e-05	0.000436	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—VEGFA—Alzheimer's disease	6.9e-05	0.000435	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HTR2A—Alzheimer's disease	6.9e-05	0.000435	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NPY—Alzheimer's disease	6.88e-05	0.000434	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IAPP—Alzheimer's disease	6.84e-05	0.000431	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PLCB1—Alzheimer's disease	6.8e-05	0.000428	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARGC1A—Alzheimer's disease	6.79e-05	0.000428	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NGFR—Alzheimer's disease	6.79e-05	0.000428	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB1—Alzheimer's disease	6.78e-05	0.000427	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NPS—Alzheimer's disease	6.77e-05	0.000427	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—HMOX1—Alzheimer's disease	6.76e-05	0.000426	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CREB1—Alzheimer's disease	6.75e-05	0.000425	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PPP3CA—Alzheimer's disease	6.74e-05	0.000425	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—F2—Alzheimer's disease	6.66e-05	0.00042	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTK2B—Alzheimer's disease	6.64e-05	0.000419	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CRH—Alzheimer's disease	6.64e-05	0.000418	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADAM10—Alzheimer's disease	6.63e-05	0.000418	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PLCB1—Alzheimer's disease	6.6e-05	0.000416	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL2—Alzheimer's disease	6.6e-05	0.000416	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR5—Alzheimer's disease	6.55e-05	0.000413	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SST—Alzheimer's disease	6.46e-05	0.000407	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GAB2—Alzheimer's disease	6.46e-05	0.000407	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NTRK2—Alzheimer's disease	6.46e-05	0.000407	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CALM1—Alzheimer's disease	6.44e-05	0.000406	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HTR2A—Alzheimer's disease	6.41e-05	0.000404	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GSK3A—Alzheimer's disease	6.41e-05	0.000404	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ABCA1—Alzheimer's disease	6.4e-05	0.000403	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NGFR—Alzheimer's disease	6.34e-05	0.0004	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB1—Alzheimer's disease	6.33e-05	0.000399	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CREB1—Alzheimer's disease	6.3e-05	0.000397	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APP—Alzheimer's disease	6.3e-05	0.000397	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NPS—Alzheimer's disease	6.29e-05	0.000397	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—S100B—Alzheimer's disease	6.27e-05	0.000395	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PPP3CA—Alzheimer's disease	6.26e-05	0.000395	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADAM10—Alzheimer's disease	6.19e-05	0.00039	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—F2—Alzheimer's disease	6.19e-05	0.00039	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—LPL—Alzheimer's disease	6.18e-05	0.00039	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTK2B—Alzheimer's disease	6.17e-05	0.000389	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL2—Alzheimer's disease	6.17e-05	0.000389	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—F2—Alzheimer's disease	6.05e-05	0.000381	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SST—Alzheimer's disease	6e-05	0.000378	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GAB2—Alzheimer's disease	6e-05	0.000378	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NTRK2—Alzheimer's disease	6e-05	0.000378	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CALM1—Alzheimer's disease	5.98e-05	0.000377	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF2—Alzheimer's disease	5.97e-05	0.000376	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GSK3A—Alzheimer's disease	5.95e-05	0.000375	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PLCB1—Alzheimer's disease	5.94e-05	0.000375	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—S100B—Alzheimer's disease	5.86e-05	0.000369	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APP—Alzheimer's disease	5.85e-05	0.000369	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1R—Alzheimer's disease	5.77e-05	0.000364	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—F2—Alzheimer's disease	5.62e-05	0.000354	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—Alzheimer's disease	5.6e-05	0.000353	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—Alzheimer's disease	5.58e-05	0.000352	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF2—Alzheimer's disease	5.58e-05	0.000352	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—Alzheimer's disease	5.57e-05	0.000351	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NGFR—Alzheimer's disease	5.54e-05	0.000349	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LPL—Alzheimer's disease	5.54e-05	0.000349	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLCB1—Alzheimer's disease	5.52e-05	0.000348	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARGC1A—Alzheimer's disease	5.52e-05	0.000348	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CREB1—Alzheimer's disease	5.51e-05	0.000347	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—Alzheimer's disease	5.49e-05	0.000346	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MEF2C—Alzheimer's disease	5.49e-05	0.000346	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADAM10—Alzheimer's disease	5.42e-05	0.000341	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1R—Alzheimer's disease	5.39e-05	0.00034	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL2—Alzheimer's disease	5.39e-05	0.00034	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCG—Alzheimer's disease	5.38e-05	0.000339	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NGF—Alzheimer's disease	5.24e-05	0.00033	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—Alzheimer's disease	5.21e-05	0.000329	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CALM1—Alzheimer's disease	5.2e-05	0.000328	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOE—Alzheimer's disease	5.18e-05	0.000327	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LPL—Alzheimer's disease	5.17e-05	0.000326	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NGFR—Alzheimer's disease	5.15e-05	0.000325	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—Alzheimer's disease	5.14e-05	0.000324	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CAV1—Alzheimer's disease	5.14e-05	0.000324	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MEF2C—Alzheimer's disease	5.12e-05	0.000323	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—S100B—Alzheimer's disease	5.12e-05	0.000323	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CREB1—Alzheimer's disease	5.12e-05	0.000323	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR5—Alzheimer's disease	5.1e-05	0.000321	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADAM10—Alzheimer's disease	5.03e-05	0.000317	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCG—Alzheimer's disease	5.03e-05	0.000317	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—LPL—Alzheimer's disease	5.02e-05	0.000317	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—Alzheimer's disease	5.01e-05	0.000316	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—Alzheimer's disease	4.99e-05	0.000315	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NGF—Alzheimer's disease	4.9e-05	0.000309	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF2—Alzheimer's disease	4.88e-05	0.000307	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR5—Alzheimer's disease	4.76e-05	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—S100B—Alzheimer's disease	4.76e-05	0.0003	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1R—Alzheimer's disease	4.71e-05	0.000297	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—Alzheimer's disease	4.71e-05	0.000297	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—Alzheimer's disease	4.66e-05	0.000294	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CALM1—Alzheimer's disease	4.66e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—Alzheimer's disease	4.64e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—Alzheimer's disease	4.64e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CAV1—Alzheimer's disease	4.6e-05	0.00029	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF2—Alzheimer's disease	4.53e-05	0.000286	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—Alzheimer's disease	4.52e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—Alzheimer's disease	4.52e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—Alzheimer's disease	4.51e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MEF2C—Alzheimer's disease	4.48e-05	0.000282	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ESR1—Alzheimer's disease	4.43e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—Alzheimer's disease	4.43e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—Alzheimer's disease	4.4e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCG—Alzheimer's disease	4.39e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1R—Alzheimer's disease	4.38e-05	0.000276	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—F2—Alzheimer's disease	4.38e-05	0.000276	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CALM1—Alzheimer's disease	4.35e-05	0.000274	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—Alzheimer's disease	4.33e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—Alzheimer's disease	4.33e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CAV1—Alzheimer's disease	4.29e-05	0.000271	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH1—Alzheimer's disease	4.28e-05	0.00027	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NGF—Alzheimer's disease	4.28e-05	0.00027	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—Alzheimer's disease	4.23e-05	0.000267	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CALM1—Alzheimer's disease	4.22e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—Alzheimer's disease	4.21e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—Alzheimer's disease	4.2e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—Alzheimer's disease	4.17e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR5—Alzheimer's disease	4.16e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MEF2C—Alzheimer's disease	4.16e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—Alzheimer's disease	4.14e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—F2—Alzheimer's disease	4.09e-05	0.000258	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCG—Alzheimer's disease	4.08e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—Alzheimer's disease	4.08e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GSK3B—Alzheimer's disease	4.02e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—Alzheimer's disease	4e-05	0.000252	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREB1—Alzheimer's disease	3.99e-05	0.000251	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NGF—Alzheimer's disease	3.98e-05	0.000251	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—Alzheimer's disease	3.96e-05	0.00025	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—Alzheimer's disease	3.9e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—Alzheimer's disease	3.88e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR5—Alzheimer's disease	3.87e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—Alzheimer's disease	3.83e-05	0.000242	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CALM1—Alzheimer's disease	3.8e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—Alzheimer's disease	3.79e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—Alzheimer's disease	3.79e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—Alzheimer's disease	3.79e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—Alzheimer's disease	3.75e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GSK3B—Alzheimer's disease	3.75e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREB1—Alzheimer's disease	3.72e-05	0.000235	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—Alzheimer's disease	3.7e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—Alzheimer's disease	3.67e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—Alzheimer's disease	3.64e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—Alzheimer's disease	3.62e-05	0.000228	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—Alzheimer's disease	3.6e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—Alzheimer's disease	3.58e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—Alzheimer's disease	3.58e-05	0.000225	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—F2—Alzheimer's disease	3.57e-05	0.000225	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—Alzheimer's disease	3.55e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CALM1—Alzheimer's disease	3.53e-05	0.000223	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—Alzheimer's disease	3.52e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—Alzheimer's disease	3.52e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.5e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—Alzheimer's disease	3.49e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—Alzheimer's disease	3.48e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—Alzheimer's disease	3.36e-05	0.000212	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—F2—Alzheimer's disease	3.32e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GSK3B—Alzheimer's disease	3.28e-05	0.000207	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREB1—Alzheimer's disease	3.25e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.25e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—Alzheimer's disease	3.25e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—Alzheimer's disease	3.24e-05	0.000204	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—Alzheimer's disease	3.18e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—Alzheimer's disease	3.15e-05	0.000199	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—Alzheimer's disease	3.13e-05	0.000197	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GSK3B—Alzheimer's disease	3.05e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREB1—Alzheimer's disease	3.02e-05	0.000191	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—Alzheimer's disease	3.01e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—Alzheimer's disease	2.98e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—Alzheimer's disease	2.96e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—Alzheimer's disease	2.95e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—Alzheimer's disease	2.93e-05	0.000185	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—Alzheimer's disease	2.91e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—Alzheimer's disease	2.88e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—Alzheimer's disease	2.84e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—Alzheimer's disease	2.78e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—Alzheimer's disease	2.76e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—Alzheimer's disease	2.74e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—Alzheimer's disease	2.71e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—Alzheimer's disease	2.7e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—Alzheimer's disease	2.64e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—Alzheimer's disease	2.53e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—Alzheimer's disease	2.53e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—Alzheimer's disease	2.5e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.43e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—Alzheimer's disease	2.41e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—Alzheimer's disease	2.39e-05	0.000151	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—Alzheimer's disease	2.34e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—Alzheimer's disease	2.3e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.26e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—Alzheimer's disease	2.24e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—Alzheimer's disease	2.22e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—Alzheimer's disease	2.21e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—Alzheimer's disease	2.21e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—Alzheimer's disease	2.15e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—Alzheimer's disease	2.06e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—Alzheimer's disease	2.05e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—Alzheimer's disease	2.04e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—Alzheimer's disease	1.9e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—Alzheimer's disease	1.89e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—Alzheimer's disease	1.88e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—Alzheimer's disease	1.78e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—Alzheimer's disease	1.77e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—Alzheimer's disease	1.74e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—Alzheimer's disease	1.73e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—Alzheimer's disease	1.62e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—Alzheimer's disease	1.6e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—Alzheimer's disease	1.55e-05	9.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—Alzheimer's disease	1.49e-05	9.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—Alzheimer's disease	1.45e-05	9.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—Alzheimer's disease	1.44e-05	9.05e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—Alzheimer's disease	1.41e-05	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—Alzheimer's disease	1.31e-05	8.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—Alzheimer's disease	1.3e-05	8.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—Alzheimer's disease	1.21e-05	7.64e-05	CbGpPWpGaD
